SynteractHCR Launches Intelligent Clinical Development Platform at DIA 2013 to Support Trial Efficiencies Globally

SAN DIEGO, June 13, 2013 /PRNewswire/ -- SynteractHCR, a leading full-service global contract research organization (CRO), will unveil its Intelligent Clinical Development platform (ICD+) at the 49^th Drug Information Association (DIA) annual meeting, June 23-27 in Boston at the Boston Convention & Exhibition Center. SynteractHCR will exhibit at booth #819.  

(Logo: http://photos.prnewswire.com/prnh/20111108/MM02925LOGO)

SynteractHCR's goal is to take time and cost out of the drug development process and deliver successful therapies to patients sooner. ICD+ is the platform by which the company leverages clinical development expertise, appropriate technology and optimized processes, tailored to each client's needs, to drive solution-oriented efficiencies on a global scale. ICD+ allows sponsors to get to decision points faster, while providing a uniform approach to trials globally to promote consistent standards and high quality.

"As we strive to streamline clinical trials and deliver better therapies in healthcare, we are confident that with ICD+, we offer a great solution to our clients," says SynteractHCR CEO Wendel Barr. "We collaborate with our clients to meet their project objectives, deliver timely results, and provide high quality work that exceeds their expectations, and ICD+ is the efficient approach we use to guide the process."

In addition, two managers from SynteractHCR will speak on Wednesday, June 26:

• Director of IT Services Toby Odenheim, MBA, will give insights on "Electronic Data Capture: The Importance and Impact of Selecting the Optimum EDC Platform for Your Clinical Program" in room 251 from 10:15-11:45 a.m.
• Senior Manager of Clinical Operations Shyla Van Reenen will participate in a study startup symposium and present "How Proactive Planning in Study Startup Drives Efficiencies in Drug Development" in room 205B from 10:15-11:45 a.m.

In March, 2013 SynteractHCR was formed from the merger of Synteract and Harrison Clinical Research (HCR), and operates from 16 locations worldwide to support Phase I-IV trials. The company's international team of clinical development experts will be available to discuss the company's full-service, multinational capabilities. To set up an appointment in advance, contact Matt Smith, SVP of Business Development at 760-795-2149 or [email protected]. The company will also host a reception at its booth on Tuesday, June 25^th at 4:00 p.m.

About SynteractHCR (www.synteracthcr.com)
SynteractHCR is a full-service contract research organization with a successful two-decade track record supporting biotechnology, medical device and pharmaceutical companies in all phases of clinical development. With its "Shared Work – Shared Vision" philosophy SynteractHCR provides customized Phase I through IV services collaboratively and cost effectively ensuring on-time delivery of quality data so clients get to decision points faster. Operating in 16 countries, SynteractHCR delivers trials internationally, offering expertise across multiple therapeutic areas including notable depth in oncology, CNS, infectious disease, endocrinology, cardiovascular, and respiratory, among other indications.

CONTACT:
Antonia Genov
[email protected]
760-230-2424

SOURCE SynteractHCR